Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers

Overview

This is a randomized, open-label Phase 1 pharmacokinetic, tolerability, and safety study of ondansetron and Hylenex given subcutaneously compared to ondansetron given intravenously, intramuscularly, and orally in normal healthy volunteers.

Full Title of Study: “Phase 1 Open-Label Randomized 4 Period Crossover Study Comparing Safety, Tolerability and PK of Ondansetron Given Subcutaneously With Hylenex Recombinant and Given Alone Intramuscularly, Intravenously and Orally in Healthy Volunteers”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 2013

Detailed Description

This is a randomized, open label, 4 way crossover Phase 1 study of the pharmacokinetics, safety and tolerability of a 4 mg dose of ondansetron administered subcutaneously with Hylenex recombinant compared to 4 mg doses of ondansetron administered intravenously and intramuscularly and an 8 mg dose of ondansetron administered orally.

Interventions

  • Drug: Ondansetron
    • Ondansetron solution 4 mg single administration
  • Drug: Ondansetron + Hylenex
    • Ondansetron solution (4 mg) single administration + Hylenex recombinant (150 U) single administration
  • Drug: Zofran ODT
    • Zofran ODT (8 mg) single administration
  • Drug: Ondansetron solution
    • Ondansetron solution (4 mg) single administration

Arms, Groups and Cohorts

  • Experimental: Subcutaneous Administration
    • Ondansetron + Hylenex administered subcutaneously
  • Experimental: Oral Administration
    • Ondansetron administered orally
  • Experimental: Intramuscular Administration
    • Ondansetron administered intramuscularly
  • Experimental: Intravenous Administration
    • Ondansetron administered intravenously

Clinical Trial Outcome Measures

Primary Measures

  • Evaluation of Overall Safety
    • Time Frame: Days 1-31
    • Investigator assessment of infusion site observations for parenteral administration; Subject assessment of pain using the verbal response scale for parenteral administration; Subject assessment of pain using the visual analog scale for parenteral administration; Investigator assessment of systemic adverse events

Secondary Measures

  • Evaluation of Pharmacokinetics
    • Time Frame: Days 1-5
    • Area of under the plasma concentration time curve (AUC); Time to achieve maximum plasma concentration (tmax); Maximum plasma concentration (Cmax); Plasma elimination half-life (t1/2); Relative bioavailability, ondansentron SC with Hylenex recombinant relative to ondansetron alone IV, IM, and PO

Participating in This Clinical Trial

Inclusion Criteria

  • Male or female volunteers 19-65 years old – Females must be nonlactating and nonpregnant (negative serum pregnancy test at screening)and agree to practice effective birth control for at least 30 days after study completion – Nonsmoker or no tobacco/nicotine use in previous 6 months – Intact normal skin without obscuring tattoos, pigmentation or lesions – Adequate venous access in upper extremities – Normal vital signs, ECG, and labs or assessed by the Investigator as NCS – Serum hemoglobin within site's normal range – Negative drug and alcohol screen – Able to make decisions and comply with study requirements Exclusion Criteria:

  • History of drug or alcohol abuse or positive drug and alcohol screen – Abdominal surgery within the last 30 days – Phenylketonuria – Tobacco or nicotine use within previous 6 months – Hypersensitivity or contraindication to ondansetron or other 5-HT3 receptor agonists – Received ondansetron within 4 days prior to Day 1 – Known allergy to hyaluronidase or other ingredient in Hylenex recombinant – Lower extremity edema – Creatinine clearance < 60 mL/min – Dehydration (Grade 2 or higher) – Hypersensitivity or contraindication to heparin – Abnormal ECG with clinically significant QT prolongation or history of – Female who is pregnant or breastfeeding – Participation in a clinical trial (drug or device) within 30 days of enrollment – Clinically significant medical history, major systemic disease, intercurrent illness, physical examination finding, or clinical laboratory test result that risks the subject's safety or interfere with interpretation of study results – Not able to comply with study requirements

Gender Eligibility: All

Minimum Age: 19 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Halozyme Therapeutics
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Samuel S Dychter, MD, Study Director, Halozyme Therapeutics

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.